ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Abstract. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics. Based on the published data, rituximab, a ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. L. Masliansky, V. I. Mazurov, E. G. Zotkin, E. P. Ilivanova, Areg A. Totolian
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	mabtera anti-в-cell therapy autoimmune diseases в-lymphocytes rituximab cd20 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/19b0e1cca39c4461af924305f349d86b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19b0e1cca39c4461af924305f349d86b
record_format	dspace
spelling	oai:doaj.org-article:19b0e1cca39c4461af924305f349d86b2021-11-18T08:03:38ZANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES1563-06252313-741X10.15789/1563-0625-2007-1-15-34https://doaj.org/article/19b0e1cca39c4461af924305f349d86b2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/116https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics. Based on the published data, rituximab, a chimeric monoclonal antibody to CD20, when used in combination with other agents (i.e., cyclophosphamide or methotrexate), appears to be a reasonable treatment option for refractory RA. There are now numerous case reports and small openlabel series using rituximab in many autoimmune diseases, others then RA. While these data must be interpreted with caution, they suggest that rituximab may be a promising addition to the therapeutic armamentarium in these diseases. However, additional controlled trials need to be conducted to confirm clinical efficacy, further define optimal dosage, response rates, comparative long-term efficacy, and treatment algorithm for rituximab in these patients.A. L. MaslianskyV. I. MazurovE. G. ZotkinE. P. IlivanovaAreg A. TotolianSPb RAACIarticlemabteraanti-в-cell therapyautoimmune diseasesв-lymphocytesrituximabcd20Immunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 9, Iss 1, Pp 15-34 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	mabtera anti-в-cell therapy autoimmune diseases в-lymphocytes rituximab cd20 Immunologic diseases. Allergy RC581-607
spellingShingle	mabtera anti-в-cell therapy autoimmune diseases в-lymphocytes rituximab cd20 Immunologic diseases. Allergy RC581-607 A. L. Masliansky V. I. Mazurov E. G. Zotkin E. P. Ilivanova Areg A. Totolian ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
description	Abstract. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics. Based on the published data, rituximab, a chimeric monoclonal antibody to CD20, when used in combination with other agents (i.e., cyclophosphamide or methotrexate), appears to be a reasonable treatment option for refractory RA. There are now numerous case reports and small openlabel series using rituximab in many autoimmune diseases, others then RA. While these data must be interpreted with caution, they suggest that rituximab may be a promising addition to the therapeutic armamentarium in these diseases. However, additional controlled trials need to be conducted to confirm clinical efficacy, further define optimal dosage, response rates, comparative long-term efficacy, and treatment algorithm for rituximab in these patients.
format	article
author	A. L. Masliansky V. I. Mazurov E. G. Zotkin E. P. Ilivanova Areg A. Totolian
author_facet	A. L. Masliansky V. I. Mazurov E. G. Zotkin E. P. Ilivanova Areg A. Totolian
author_sort	A. L. Masliansky
title	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
title_short	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
title_full	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
title_fullStr	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
title_full_unstemmed	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
title_sort	anti-b cell therapy of autoimmune diseases
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/19b0e1cca39c4461af924305f349d86b
work_keys_str_mv	AT almasliansky antibcelltherapyofautoimmunediseases AT vimazurov antibcelltherapyofautoimmunediseases AT egzotkin antibcelltherapyofautoimmunediseases AT epilivanova antibcelltherapyofautoimmunediseases AT aregatotolian antibcelltherapyofautoimmunediseases
_version_	1718422527438487552

ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Ejemplares similares